Lipoprotein profiles in children with two common cholesteryl ester transfer protein gene mutations, D442G and I14A, during the first year of life

Nagasaka, Hironori; Yorifuji, Tohru; Momoi, Toru; Yorifuji, Junko; Hirano, Ken‐ichi; Ota, Akemi; Takatani, Tomozumi; Tsukahara, Hirokazu; Takayanagi, Masaki; Kobayashi, Kunihiko; Chiba, Hitoshi; Sato, Yukiyasu; Miida, Takashi

doi:10.1016/j.cca.2009.05.007

Cited by 5 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 ApoE-containing HDL-C increases in patients with cholestasis [17][18][19][20] and those with cholesteryl ester transfer protein (CETP) deficiency. 10,14,15,21,22 Additionally, synthetic CETP inhibitors are known to increase apoE-containing HDL. [23][24][25] ApoE-containing HDL can be divided into two subspecies: one is small in size and cholesterol poor (apoE-containing HDL 3 ) and the other is large and cholesterol rich (apoE-containing HDL 2 ).…”

Section: Introductionmentioning

confidence: 99%

“…A precipitation method using 13% (w/v) polyethylene glycol (PEG) and sodium phosphotungstatedextran sulphate-MgCl 2 (PT-DS-Mg þþ ) for differential measurement of apoE-deficient and apoE-containing HDL-C has been reported by Chiba et al [13][14][15]20 This assay was used to show an increase in apoE-containing HDL-C in the patients with cholestatic liver disease 13,20,[28][29][30] and CETP deficiency. 14,15,22 However, a more convenient homogeneous assay would have been highly useful for both routine measurements and large-scale clinical and epidemiological studies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A two-step homogeneous assay for apolipoprotein E-containing high-density lipoprotein-cholesterol

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background Apolipoprotein E-containing high-density lipoprotein shows antiatherogenic properties in vitro. There is a need for a homogeneous assay to determine the concentration of apolipoprotein E-containing high-density lipoprotein for in vivo studies. Methods In the proposed homogeneous assay, lipoproteins other than apolipoprotein E-containing high-density lipoprotein were eliminated in the first step. Apolipoprotein E-containing high-density lipoprotein-cholesterol was measured in the second step. The control study used a 13% polyethylene glycol precipitation assay (control assay). Results The homogeneous assay showed good performance in validation studies. In subjects with normal liver function ( n = 78), a significant correlation was found between the control assay and the homogeneous assay ( r = 0.824). Serum apolipoprotein E-containing high-density lipoprotein cholesterol concentrations, determined by the control assay and the homogeneous assay, respectively, were 0.05 (0.04-0.10) (median [25th-75th percentile]) mmol/L and 0.10 (0.06-0.13) mmol/L for healthy individuals ( n = 12), and 0.03 (0.01-0.13) mmol/L and 0.02 (0.01-0.02) mmol/L for patients with cholestasis ( n = 6). The results indicate that the homogeneous assay recovers cholesterol contained in physiological apolipoprotein E-containing high-density lipoprotein, but not in pathological apolipoprotein E-containing high-density lipoprotein from cholestatic patients. Conclusions The proposed two-step homogeneous assay enables selective measurement of physiological apolipoprotein E-containing high-density lipoprotein cholesterol in common autoanalysers. This assay might uncover a role for apolipoprotein E-containing high-density lipoprotein in physiological conditions.

show abstract